Evidence map›Paper›PMID 41580872›Full record

ArticlePneumonia (Nathan Qld.)2026

Evaluation of PSI, CURB-65, and CRB-65 as prognostic tools in hospitalized immunocompetent patients with pneumonia: real-world outcomes from internal medicine wards.

Alon Pomerantz, Adar Yaacov, Adam Goldman, Yonatan Moshkovits, Asaf Zlotnik, Ofir Deri, Liran Levy

Abstract read
In one paragraph

Article in Pneumonia (Nathan Qld.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alon PomerantzSchool of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel. alon.pomerantz@sheba.health.gov.il.
Adar YaacovHelmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel.
Adam GoldmanInternal Medicine Department, Sheba Medical Center, Tel-Hashomer, Israel.
Yonatan MoshkovitsSchool of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
Asaf ZlotnikSchool of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
Ofir DeriSchool of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
Liran LevySchool of Medicine, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumonia remains a leading cause of morbidity and mortality globally, necessitating reliable clinical prediction tools to guide medical management decisions. The Pneumonia Severity Index (PSI), CURB-65, and CRB-65 are clinical scoring tools used to assess the severity of community-acquired pneumonia (CAP), aiding in risk stratification and guiding decisions on hospitalization, level of care and prognosis. Comparative data on their utility, specifically in immunocompetent patients hospitalized in internal medicine wards, are limited. This study aimed to evaluate the predictive capabilities of these scoring tools for mortality and intensive care unit (ICU) transfers in a large cohort of hospitalized patients.

methodsWe conducted a retrospective, single-center cohort study including 12,670 immunocompetent patients hospitalized with pneumonia in the internal medicine division. PSI, CURB-65, and CRB-65 performance was compared across multiple outcomes, including in-hospital mortality, 30-, 60-, 90-day mortality, and ICU transfer from ward. Subgroup analyses were performed for key comorbidities (chronic obstructive pulmonary disease [COPD], congestive heart failure [CHF], diabetes, chronic kidney disease [CKD] and hypertension).

resultsPSI consistently demonstrated significantly superior discrimination between survivors and non-survivors across all mortality outcomes with AUC range of 0.73–0.75 (p < 0.001, FDR-corrected). In the subgroup analysis by comorbidities, PSI was significantly superior to the other scoring systems only in diabetes patients in 60 and 90-day mortality (AUC = 0.70–0.71). CURB-65 performed comparably to PSI in most of the cases and was superior to CRB-65 only in diabetes and hypertension patients. When predicting ICU transfer during hospitalization, there were no significant differences between the scoring tools, and all demonstrated low predictive capability.

conclusionThe PSI demonstrates superior discriminative ability in immunocompetent patients hospitalized with pneumonia. However, its greater complexity should be considered when evaluating its practicality for routine use.

Indexed as

CRB-65CURB-65Immunocompetent patientsInternal medicineMortality predictionPneumoniaPSI

Identifiers

PMID41580872
PMCPMC12832007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.